@FierceMedDev: ICYMI: Study: 3-D tissue marker helps improve breast cancer monitoring, aids recovery. Article | Follow @FierceMedDev
@VarunSaxena2: Four key medical device recalls of 2015. Feature | Follow @VarunSaxena2
@EmilyWFierce: ICYMI: EU regulators crack down on Brazilian devicemaker for implant safety scare. Article | Follow @EmilyWFierce
> The GE Foundation is leading an effort to commit $25 million over three years to improve to improve global surgical capacity, infrastructure, and training. More
> NEA-backed startup Cartiva has started a clinical trial for its Synthetic Cartilage Implant (SCI) in the treatment of first carpometacarpal (CMC) joint osteoarthritis at the base of the thumb. More
> Bolton Medical has gotten a CE mark or its Treo Abdominal Stent-Graft System used to treat abdominal aortic aneurysms (AAAs). More
Biotech News
@FierceBiotech: ICYMI: Aduro adds checkpoint inhibitors to a 'breakthrough' mix in $32M buyout. Article | Follow @FierceBiotech
@JohnCFierce: Think the drug pricing issue is going away? Washington Post: The secret truth. Report | Follow @JohnCFierce
@DamianFierce: As a longtime appreciator of dumb corporate M&A codenames, "Project Potsticker" is a solid addition. Bloomberg story | Follow @DamianFierce
> Troubled GlaxoSmithKline to shutter R&D facility in France. Story
> Roche, Boehringer and Gilead line up for EU drug approvals. News
> AbbVie dumps Galapagos' arthritis drug and presses on with its own. Article
Pharma News
@FiercePharma: Investors trounce Aratana on dashed hopes for canine lymphoma drugs. FierceAnimalHealth article | Follow @FiercePharma
@EricPFierce: Sun Pharma unit Mutual Pharma recalls 216,766 bottles that may have chemical leaching labels. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: Proud to say my home state is like, basically, the champion of pumpkin-growing. Where America's pumpkins come from. More | Follow @CarlyHFierce
> Novartis scores EU rec for blockbuster-to-be Entresto. News
> Alexion sues Canada over Soliris price cut attempt as drug cost debate explodes on center stage. Story
> Shire chalks up victory in Vyvanse patent battle. Report
